Rob Ring -- Chief Science Officer
Rob Ring, Chief Science Officer
Rob Ring was named Chief Science Officer in June of 2013.
first goal would be to "put science to work for our families," and that makes perfect sense given his
Rob first joined Autism Speaks
in June of 2011 as Vice President of Translational Research.
In that role, Rob
was responsible for the development and implementation of the foundation's expanding translational research portfolio, which serves to accelerate the process of converting scientific breakthroughs and innovations in technology into actual products that address the wide range of unmet needs of the autism community, from healthcare to education to daily living.
Rob also serves as President of Delivering Scientific Innovation for Autism (DELSIA), the venture philanthropy arm of Autism Speaks that is helping to facilitate translational activities in the for-profit sector required to develop commercial products that will improve the quality of life and health for individuals with autism.
Prior to joining Autism Speaks, Rob served as Senior Director and Head of the Autism Research Unit at Pfizer Worldwide Research and Development in Groton, Conn.
There he led the first dedicated research group in the pharmaceutical industry focused specifically on the discovery and development of medicines for neurodevelopmental disorders, specifically ASD.
Prior to Pfizer, Rob worked for over 10 years in psychiatric medicines discovery and development at Wyeth Research in Princeton, N.J.
Rob earned a B.A. double major in both Fine Art and Biology from Westmont College in Santa Barbara, Calif., and a Ph.D. in Molecular Neurobiology from City of Hope in Southern California.
holds adjunct faculty appointments in the Departments of Psychiatry at Mount Sinai School of Medicine (N.Y.) and Pharmacology and Physiology at Drexel University College of Medicine (Philadelphia).